List of Supernus Pharmaceuticals, Inc. patents

Patents where

Current Assignee

Name

‌

Supernus Pharmaceuticals, Inc.

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7611728 Osmotic delivery of therapeutic compounds by solubility enhancement	Patent 7611728 was granted and assigned to Supernus Pharmaceuticals, Inc. on November, 2009 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	7611728	November 3, 2009
‌ US Patent 8193211 Controlled release compositions of gamma-hydroxybutyrate	Patent 8193211 was granted and assigned to Supernus Pharmaceuticals, Inc. on June, 2012 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	8193211	June 5, 2012
‌ US Patent 9370525 Modified release preparations containing oxcarbazepine and derivatives thereof	Patent 9370525 was granted and assigned to Supernus Pharmaceuticals, Inc. on June, 2016 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9370525	June 21, 2016
‌ US Patent 9855278 Modified release preparations containing oxcarbazepine and derivatives thereof	Patent 9855278 was granted and assigned to Supernus Pharmaceuticals, Inc. on January, 2018 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9855278	January 2, 2018
‌ US Patent 11351120 Use of higher doses of modified release huperzine formulations		‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	11351120	June 7, 2022
‌ US Patent 9351975 Modified release preparations containing oxcarbazepine and derivatives thereof	Patent 9351975 was granted and assigned to Supernus Pharmaceuticals, Inc. on May, 2016 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9351975	May 31, 2016
‌ US Patent 9119791 Modified release preparations containing oxcarbazepine and derivatives thereof	Patent 9119791 was granted and assigned to Supernus Pharmaceuticals, Inc. on September, 2015 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9119791	September 1, 2015
‌ US Patent 7410978 Once daily dosage forms of trospium	Patent 7410978 was granted and assigned to Supernus Pharmaceuticals, Inc. on August, 2008 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	7410978	August 12, 2008
‌ US Patent 7910131 Method of treating seizures using modified release formulations of oxcarbazepine	Patent 7910131 was granted and assigned to Supernus Pharmaceuticals, Inc. on March, 2011 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	7910131	March 22, 2011
‌ US Patent 7722898 Modified-release preparations containing oxcarbazepine and derivatives thereof	Patent 7722898 was granted and assigned to Supernus Pharmaceuticals, Inc. on May, 2010 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	7722898	May 25, 2010
‌ US Patent 10220042 Modified release preparations containing oxcarbazepine and derivatives thereof	Patent 10220042 was granted and assigned to Supernus Pharmaceuticals, Inc. on March, 2019 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	10220042	March 5, 2019
‌ US Patent 7300794 Accelerated culture system for intestinal epithelial cell monolayers	Patent 7300794 was granted and assigned to Supernus Pharmaceuticals, Inc. on November, 2007 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	7300794	November 27, 2007
‌ US Patent 10265319 Formulations of viloxazine	Patent 10265319 was granted and assigned to Supernus Pharmaceuticals, Inc. on April, 2019 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	10265319	April 23, 2019
‌ US Patent 9603853 Formulations of viloxazine	Patent 9603853 was granted and assigned to Supernus Pharmaceuticals, Inc. on March, 2017 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9603853	March 28, 2017
‌ US Patent 9662338 Formulations of viloxazine	Patent 9662338 was granted and assigned to Supernus Pharmaceuticals, Inc. on May, 2017 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9662338	May 30, 2017
‌ US Patent 11458143 Method of treatment of attention deficit/hyperactivity disorder (ADHD)		‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	11458143	October 4, 2022
‌ US Patent 11324753 Method of treatment of attention deficit/hyperactivity disorder (ADHD)	Patent 11324753 was granted and assigned to Supernus Pharmaceuticals, Inc. on May, 2022 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	11324753	May 10, 2022
‌ US Patent 8598191 Controlled release compositions of gamma-hydroxybutyrate	Patent 8598191 was granted and assigned to Supernus Pharmaceuticals, Inc. on December, 2013 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	8598191	December 3, 2013
‌ US Patent 9358204 Formulations of viloxazine	Patent 9358204 was granted and assigned to Supernus Pharmaceuticals, Inc. on June, 2016 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9358204	June 7, 2016
‌ US Patent 11638708 Method of treatment of aggression	Patent 11638708 was granted and assigned to Supernus Pharmaceuticals, Inc. on May, 2023 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	11638708	May 2, 2023
‌ US Patent 9434703 Viloxazine compositions	Patent 9434703 was granted and assigned to Supernus Pharmaceuticals, Inc. on September, 2016 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9434703	September 6, 2016
‌ US Patent 9562011 Methods of producing molindone and its salts	Patent 9562011 was granted and assigned to Supernus Pharmaceuticals, Inc. on February, 2017 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9562011	February 7, 2017
‌ US Patent 9403783 Methods for producing viloxazine salts and novel polymorphs thereof	Patent 9403783 was granted and assigned to Supernus Pharmaceuticals, Inc. on August, 2016 by the United States Patent and Trademark Office.		‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9403783	August 2, 2016
‌ US Patent 8957206 Methods of producing molindone and its salts	Patent 8957206 was granted and assigned to Supernus Pharmaceuticals, Inc. on February, 2015 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	8957206	February 17, 2015
‌ US Patent 9802893 Methods of producing molindone and its salts	Patent 9802893 was granted and assigned to Supernus Pharmaceuticals, Inc. on October, 2017 by the United States Patent and Trademark Office.	‌ Supernus Pharmaceuticals, Inc.	‌ Supernus Pharmaceuticals, Inc.	United States Patent and Trademark Office	9802893	October 31, 2017

Results per page:

75 results

0 selected

75 results

0 selected